To include your compound in the COVID-19 Resource Center, submit it here.

AZX100: Final Phase IIa data

Final data from the double-blind Phase IIa OL-ASCAR-03 trial in 146 patients showed that 3 and 10 mg intradermal AZX100 administered 9 and 21 days following arthroscopic shoulder surgery missed

Read the full 306 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE